Following this multi-tumor screening, the large NSCLC, ovarian cancer, and pancreatic adenocarcinoma cohorts were used to further explore patterns of CD40 expression, as well as potential prognostic value and possible correlations with clinicopathologic features. The gene discussed is CD40; the disease is ovarian carcinoma.